- April 7, 2018
- Posted by: PharmaScroll
- Category:
As per a latest draft guidance issued by National Institute for Health and Care Excellence (NICE), ocrelizumab is not recommended, within its marketing authorisation, for treating relapsing forms of multiple sclerosis in adults with active disease defined by clinical or imaging features.
The recommendation though would not affect the treatment with ocrelizumab that was started in the NHS before the guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.
Current NHS treatments for relapsing forms of multiple sclerosis include alemtuzumab, beta interferons, cladribine, dimethyl fumarate, fingolimod, glatiramer acetate, natalizumab and teriflunomide.
NICE further stated in the recommendation that, Clinical trial results show that ocrelizumab reduces the number of relapses and slows disability progression compared with interferon beta-1a for people with relapsing–remitting multiple sclerosis. There is no evidence directly comparing ocrelizumab with other treatments. Indirect analyses suggest that ocrelizumab reduces the number of relapses compared with interferon beta-1b, glatiramer acetate, dimethyl fumarate, fingolimod and teriflunomide, and is as effective as alemtuzumab and natalizumab. However, from these analyses, it is uncertain whether ocrelizumab slows disease progression compared with other treatments, particularly in the subgroups of highly active disease and rapidly evolving severe disease.
NICE highlighted that the most plausible cost-effectiveness estimates for ocrelizumab compared with all relevant comparators are higher than those NICE normally considers an acceptable use of NHS resources.
Based on the recommendation issued, it seems that the blockbuster drug ocrelizumab, which has seen strong uptakes in the other launched markets, would have to wait sometime further to gain access in the UK market.
About Pharmascroll:
Pharmascroll is a diligent business consulting and market research firm focused solely towards pharmaceutical markets. The company consults and researches in majorly chronic disease indications prevalent across the globe. The research conducted by Pharmascroll analysts is targeted to provide analytical and logical answers to the key business questions of the pharmaceutical and medical insights teams and to make better informed business decisions with the detailed relevant information available.
To read more news about Multiple Sclerosis, visit https://pharmascroll.com/news-category/multiple-sclerosis/
News Source: https://www.nice.org.uk/guidance/GID-TA10152/documents/appraisal-consultation-document
Image Source: https://liveclinic.com/blog/difference-denied-rejected-claim-medical-billing/